|GRANTWAY
EN

Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)

National Institutes of Health

Share
Favorite
Feedback
Summary
-
14 August 2025
-
-
-
For profit
Not for profit (incl. NGOs)
Public sector
R&D and Higher Education
-
Education, Skills Building and Training Health, Justice and Social Welfare
Overview

The goal of this funding opportunity announcement is to generate brain region and cell-type specific microglial protein profiles in the context of HIV and SUD, then use those molecular profiles and interaction networks to establish mechanisms of how HIV-harboring microglia may contribute specifically to neuropathologies encountered with comorbid HIV and SUD.

Eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Learn more or apply
All information about this funding has been collected from and belongs to the funding organization
21 July 2023